{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00025153", "CSN": null, "TRF": "ORD_1514792_01", "MRN": "33525018", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1233819", "clinicalId": "1235189", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1514792_01", "SampleName": "US1450019.01", "Version": "0", "Sample": {"FM_Id": "ORD_1514792_01", "SampleId": "US1450019.01", "BlockId": "nan", "TRFNumber": "ORD_1514792_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_12_01", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "13", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M111-10031", "MRN": "33525018", "FullName": "\u65b9\u5a1f\u5a1f", "FirstName": "Chuan_Chuan", "LastName": "Fang", "SubmittedDiagnosis": "Sarcoma, Soft tissue", "Gender": "Female", "DOB": "1968_08_29", "OrderingMD": "\u984f\u53a5\u5168", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_11_28", "ReceivedDate": "2022-12-14 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "19", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "G743V"}, {"geneName": "CARD11", "isVUS": "true", "variantName": "A209T"}, {"geneName": "DOT1L", "isVUS": "true", "variantName": "A438T"}, {"geneName": "FAM123B", "isVUS": "true", "variantName": "D919A"}, {"geneName": "FANCA", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "A1361T"}, {"geneName": "MED12", "isVUS": "true", "variantName": "I2047V"}, {"geneName": "NF2", "isVUS": "true", "variantName": "R462H"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "Q1134R"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "A1450T"}, {"geneName": "PTCH1", "isVUS": "true", "variantName": "R1342H"}, {"geneName": "RARA", "isVUS": "true", "variantName": "T285A"}, {"geneName": "ROS1", "isVUS": "true", "variantName": "S2255L"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "05", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "05"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (PubMed, Mar 2022). Published data investigating the prognostic implications of bTMB levels in sarcoma are limited (PubMed, Jul 2022). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2022). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased blood tumor mutational burden (bTMB) may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1 (Schenker et al., 2022; AACR Abstract CT022, Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074, Saori et al., 2021; ESMO Abstract 80P, Sturgill et al., 2022; 35274716), anti_PD_1/CTLA4 therapies (Schenker et al., 2022; AACR Abstract CT022, Saori et al., 2021; ESMO Abstract 80P), anti_PD_L1/CTLA4 therapies (Chen et al., 2020; 32379280, Loree et al., 2021; ASCO GI Abstract 61, Li et al., 2020; ASCO Abstract 6511, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). A Phase 2 multi_solid_tumor trial showed that bTMB \u226516 Muts/Mb (as measured by this assay) was associated with improved survival from treatment with a PD_1 inhibitor alone or in combination with a CTLA_4 inhibitor (Schenker et al., 2022; AACR Abstract CT022). In non_small cell lung cancer (NSCLC), multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single_agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 Muts/Mb_16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2020; 32271377, Si et al., 2021; 33355200, Leighl et al., 2022; 34800700). In head and neck squamous cell carcinoma (HNSCC), a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511). In colorectal cancer (CRC), a Phase 2 study showed that bTMB TMB \u226528 Muts/Mb (approximate equivalency \u226514 Muts/Mb as measured by this assay) was associated with improved OS from a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Loree et al., 2021; ASCO GI Abstract 61, Chen et al., 2020; 32379280). It is not known whether any targeted therapeutic approach would be relevant in the context of non_malignant conditions, as observed here.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "DNMT3A", "Include": "true", "Alterations": {"Alteration": {"Name": "V675fs*29", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "0.63", "isEquivocal": "false", "name": "V675fs*29"}}, "Interpretation": "The DNMT3A gene encodes the protein DNA methyltransferase 3A, an enzyme that is involved in the methylation of newly synthesized DNA, a function critical for gene regulation (Trowbridge and Orkin, 2012; 22200773, Ch\u00e9din, 2011; 21507354). The role of DNMT3A in cancer is uncertain, as some reports describe increased expression and contribution to tumor growth, whereas others propose a role for DNMT3A as a tumor suppressor (Yang et al., 2011; 21887466, Vallb\u00f6hmer et al., 2006; 16870044, Daskalos et al., 2011; 21351083, Fabbri et al., 2007; 17890317, Gao et al., 2011; 22011581, Kim et al., 2013; 23031157). Alterations such as seen here may disrupt DNMT3A function or expression (Chen et al., 2005; 15861382, Guo et al., 2015; 25383530, Sandoval et al., 2019; 30705090, Zhang et al., 2018; 29414941). DNMT3A alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Feb 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of DNMT3A alterations in solid tumors are limited (PubMed, Feb 2022). There are no targeted therapies available to address genomic alterations in DNMT3A in solid tumors. It is not known whether any targeted therapeutic approach would be relevant in the context of non_malignant conditions, as observed here. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, 25% of which were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). Smaller studies have reported MSI at any level in a subset of liposarcoma patients (Davis et al., 2014; 24878023, Suwa et al., 1999; 10370164) or reported as absent in 21 cases analyzed (Schneider_Stock et al., 1999; 10087320). Microsatellite status has not been studied specifically in lipoma (PubMed, Mar 2022). The prognostic significance of MSI in liposarcoma is unknown (PubMed, Mar 2022). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). It is not known whether any targeted therapeutic approach would be relevant in the context of non_malignant conditions, as observed here. As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "NF1", "Include": "true", "Alterations": {"Alteration": {"Name": "R2583fs*12", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "4.58", "isEquivocal": "false", "name": "R2583fs*12"}}, "Interpretation": "NF1 encodes neurofibromin, a GTPase_activating protein (GAP) that is a key negative regulator of the RAS signaling pathway (Hattori et al., 1991; 1904223). Neurofibromin acts as a tumor suppressor by repressing RAS signaling (Morcos et al., 1996; 8628317). The consequences of alterations that may leave the GAP_related domain intact, such as seen here, are unclear; however, similar alterations have been previously reported in the context of cancer, which may indicate biological relevance. NF1 alterations are common in various solid tumors, with mutations being more frequent than gene loss, and are often seen in melanoma (18%), glioma (14%), gastrointestinal stromal tumor (GIST; 10%), and in salivary gland (6.1%), ovarian (5.4%), breast (4.8%), non_small cell lung (4.7%), non_melanoma skin (4.7%), and endometrial (3.7%) cancer (cBio_Zehir et al., 2017; 28481359). There are rare reports of leiomyosarcoma arising in patients with neurofibromatosis with the assumption of NF1 mutation (Liew et al., 2002; 11910511, Kluger et al., 2009; 19946501). The appearance of soft tissue sarcoma in patients with neurofibromatosis is associated with a poor prognosis (Bien et al., 2008; 18663267). On the basis of clinical evidence in neurofibromatosis Type 1_associated neurofibroma (Dombi et al., 2016; 28029918, Schalkwijk et al., 2021; 33903938, Glassberg et al., 2020; ASPHO Abstract 2015, Coyne et al., 2020; ASCO Abstract 3612, McCowage et al., 2018; ASCO Abstract 10504, Mueller et al., 2020; SNO Abstract NFB_17, Toledano et al., 2021; 33751171, Waldner et al., 2020; DOI: 10.1055/s_0040_1715638, Ronsley et al., 2021; 33939292), glioma or glioblastoma (Fangusaro et al., 2019; 31151904, Manoharan et al., 2020; 32780261, Kondyli et al., 2018; 30097824, Ronsley et al., 2021; 33939292, Romo et al., 2019; SNO Abstract RARE_54, Awada et al., 2020; 33082744), and non_small cell lung cancer (Middleton et al., 2020; 32669708), NF1 inactivation may predict sensitivity to MEK inhibitors such as cobimetinib, trametinib, binimetinib, and selumetinib. On the basis of limited clinical data (Lim et al., 2016; 26859683 , Weiss et al., 2015; 25314964, Janku et al., 2014; 24931142) and preclinical data (Johannessen et al., 2008; 18164202, Johannessen et al., 2005; 15937108), loss or inactivation of NF1 may predict sensitivity to mTOR inhibitors, including everolimus and temsirolimus. A preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1_deficient malignant peripheral nerve sheath tumors (MPNST) (Malone et al., 2014; 24913553). It is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. It is not known whether any targeted therapeutic approach would be relevant in the context of non_malignant conditions, as observed here. One or more of the NF1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with neurofibromatosis type 1 (ClinVar, Sep 2022)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms (Jett and Friedman, 2010; 20027112, Patil and Chamberlain, 2012; 22240541, Evans et al., 2012; 23036231). Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,000 (Upadhyaya et al., 1995; 8544190, Williams et al., 2009; 19117870), and in the appropriate clinical context, germline testing of NF1 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PTCH1", "Include": "true", "Alterations": {"Alteration": {"Name": "I941fs*18", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "3.68", "isEquivocal": "false", "name": "I941fs*18"}}, "Interpretation": "The PTCH1 tumor suppressor gene encodes a 12_transmembrane protein that functions as an inhibitor of Smoothened (SMO) and downstream Hedgehog (Hh) signaling (Taipale et al., 2002; 12192414). PTCH1 is a receptor for Hh ligands (Stone et al., 1996; 8906787) and Hh ligand binding to PTCH1 results in derepression of SMO and downstream activation GLI_family transcription factors (Stanton and Peng, 2010; 20024066). Inactivating germline mutations in PTCH1 are associated with Basal Cell Nevus Syndrome (Gorlin syndrome) (Johnson et al., 1996; 8658145, Hahn et al., 1996; 8681379). Patients with Gorlin syndrome develop basal cell carcinomas and are also predisposed to medulloblastoma. Somatic mutations that inactivate PTCH1 are frequently found in the sporadic forms of these cancers. Alterations such as seen here may disrupt PTCH1 function or expression. PTCH1 alterations including characterized loss of function mutations (Yauch et al., 2009; 19726788, Chung and Bunz., 2013; 24368541), or alterations that are associated with Gorlin syndrome (Sharpe et al., 2015; 25759019) or Sonic Hedgehog subgroup medulloblastoma (Kool et al., 2014; 24651015, Pugh et al., 2012; 22820256, Jones et al., 2012; 22832583), are predicted to result in increased Hedgehog signaling; patients with PTCH1 mutations have had significant clinical responses to SMO inhibitors (Rudin et al., 2009; 19726761, Von Hoff et al., 2009; 19726763). Inactivating PTCH1 alterations are rare in sarcoma and have been reported in 2% (1/50) of the dedifferentiated liposarcomas analyzed in the MSKCC sarcoma dataset (cBio_Barretina et al., 2010; 20601955). Published data investigating the prognostic implications of PTCH1 alteration in liposarcoma are limited (PubMed, Dec 2022). Activation of SMO or loss of PTCH1 can result in activation of downstream Hedgehog signaling (Hh) (Shou et al., 2015; 25473003, Rodon et al., 2014; 24523439, Migden et al., 2015; 25981810, Kieran et al., 2017; 28605510) and may predict sensitivity to SMO inhibitors such as vismodegib (Von Hoff et al., 2009; 19726763, Rudin et al., 2009; 19726761, Robinson et al., 2015; 26169613, Frappaz et al., 2021; 33825892) and sonidegib (Lear et al., 2020; 32104037). Clinical responses to vismodegib have been reported for patients with PTCH1_mutated basal cell carcinoma (BCC) (1/8 CR, 5/8 PR) (Von Hoff et al., 2009; 19726763) and medulloblastoma (DCR 70%, 7/10) (Robinson et al., 2015; 26169613). In other tumor types, the efficacy of vismodegib and sonidegib is more limited. In a basket trial, 17% (3/18) of patients with PTCH1_mutated tumors achieved a PR from vismodegib (Hainsworth et al., 2018; 29320312). An additional basket trial reported all 6 patients with PTCH1 alterations experienced PD from sonidegib (Slosberg et al., 2018; 29765547). It is not known whether any targeted therapeutic approach would be relevant in the context of non_malignant conditions, as observed here.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207). It is not known whether any targeted therapeutic approach would be relevant in the context of non_malignant conditions, as observed here.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "1", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "2", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "3", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "4", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "5", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "6", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "7", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "8", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "9", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "10", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "11", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "12", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "13", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "14", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "15", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "16", "ReferenceId": "12192414", "FullCitation": "Taipale J, et al. Nature (2002) pmid: 12192414", "Include": "true"}, {"number": "17", "ReferenceId": "8906787", "FullCitation": "Stone DM, et al. Nature (1996) pmid: 8906787", "Include": "true"}, {"number": "18", "ReferenceId": "20024066", "FullCitation": "Stanton BZ, et al. Mol Biosyst (2010) pmid: 20024066", "Include": "true"}, {"number": "19", "ReferenceId": "8658145", "FullCitation": "Johnson RL, et al. Science (1996) pmid: 8658145", "Include": "true"}, {"number": "20", "ReferenceId": "8681379", "FullCitation": "Hahn H, et al. Cell (1996) pmid: 8681379", "Include": "true"}, {"number": "21", "ReferenceId": "19726788", "FullCitation": "Yauch RL, et al. Science (2009) pmid: 19726788", "Include": "true"}, {"number": "22", "ReferenceId": "24368541", "FullCitation": "Chung JH, et al. Oncotarget (2013) pmid: 24368541", "Include": "true"}, {"number": "23", "ReferenceId": "25759019", "FullCitation": "Sharpe HJ, et al. Cancer Cell (2015) pmid: 25759019", "Include": "true"}, {"number": "24", "ReferenceId": "24651015", "FullCitation": "Kool M, et al. Cancer Cell (2014) pmid: 24651015", "Include": "true"}, {"number": "25", "ReferenceId": "22820256", "FullCitation": "Pugh TJ, et al. Nature (2012) pmid: 22820256", "Include": "true"}, {"number": "26", "ReferenceId": "22832583", "FullCitation": "Jones DT, et al. Nature (2012) pmid: 22832583", "Include": "true"}, {"number": "27", "ReferenceId": "19726761", "FullCitation": "Rudin CM, et al. N. Engl. J. Med. (2009) pmid: 19726761", "Include": "true"}, {"number": "28", "ReferenceId": "19726763", "FullCitation": "Von Hoff DD, et al. N. Engl. J. Med. (2009) pmid: 19726763", "Include": "true"}, {"number": "29", "ReferenceId": "20601955", "FullCitation": "Barretina J, et al. Nat. Genet. (2010) pmid: 20601955", "Include": "true"}, {"number": "30", "ReferenceId": "25473003", "FullCitation": "Shou Y, et al. Clin. Cancer Res. (2015) pmid: 25473003", "Include": "true"}, {"number": "31", "ReferenceId": "24523439", "FullCitation": "Rodon J, et al. Clin. Cancer Res. (2014) pmid: 24523439", "Include": "true"}, {"number": "32", "ReferenceId": "25981810", "FullCitation": "Migden MR, et al. Lancet Oncol. (2015) pmid: 25981810", "Include": "true"}, {"number": "33", "ReferenceId": "28605510", "FullCitation": "Kieran MW, et al. Neuro Oncol (2017) pmid: 28605510", "Include": "true"}, {"number": "34", "ReferenceId": "26169613", "FullCitation": "Robinson GW, et al. J. Clin. Oncol. (2015) pmid: 26169613", "Include": "true"}, {"number": "35", "ReferenceId": "33825892", "FullCitation": "Frappaz D, et al. Neuro Oncol (2021) pmid: 33825892", "Include": "true"}, {"number": "36", "ReferenceId": "32104037", "FullCitation": "Lear JT, et al. Clin Cosmet Investig Dermatol (2020) pmid: 32104037", "Include": "true"}, {"number": "37", "ReferenceId": "29320312", "FullCitation": "Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312", "Include": "true"}, {"number": "38", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "39", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "40", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "41", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "42", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "43", "ReferenceId": "24878023", "FullCitation": "Davis JL, et al. Arch. Pathol. Lab. Med. (2014) pmid: 24878023", "Include": "true"}, {"number": "44", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "45", "ReferenceId": "10087320", "FullCitation": "Schneider_Stock R, et al. Int. J. Oncol. (1999) pmid: 10087320", "Include": "true"}, {"number": "46", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "47", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "48", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "49", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "50", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "51", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "52", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "53", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "54", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "55", "ReferenceId": "1904223", "FullCitation": "Hattori S, et al. Biochem. Biophys. Res. Commun. (1991) pmid: 1904223", "Include": "true"}, {"number": "56", "ReferenceId": "8628317", "FullCitation": "Morcos P, et al. Mol. Cell. Biol. (1996) pmid: 8628317", "Include": "true"}, {"number": "57", "ReferenceId": "28481359", "FullCitation": "Zehir A, et al. Nat. Med. (2017) pmid: 28481359", "Include": "true"}, {"number": "58", "ReferenceId": "11910511", "FullCitation": "Liew MA, et al. Pediatr. Dev. Pathol. () pmid: 11910511", "Include": "true"}, {"number": "59", "ReferenceId": "19946501", "FullCitation": "Kluger N, et al. Cases J (2009) pmid: 19946501", "Include": "true"}, {"number": "60", "ReferenceId": "18663267", "FullCitation": "Bie\u0144 E, et al. Med Wieku Rozwoj () pmid: 18663267", "Include": "true"}, {"number": "61", "ReferenceId": "28029918", "FullCitation": "Dombi E, et al. N. Engl. J. Med. (2016) pmid: 28029918", "Include": "true"}, {"number": "62", "ReferenceId": "33903938", "FullCitation": "Schalkwijk S, et al. Cancer Chemother Pharmacol (2021) pmid: 33903938", "Include": "true"}, {"number": "63", "ReferenceId": "33751171", "FullCitation": "Toledano H, et al. Childs Nerv Syst (2021) pmid: 33751171", "Include": "true"}, {"number": "64", "ReferenceId": "33939292", "FullCitation": "Ronsley R, et al. Cancer Med (2021) pmid: 33939292", "Include": "true"}, {"number": "65", "ReferenceId": "31151904", "FullCitation": "Fangusaro J, et al. Lancet Oncol. (2019) pmid: 31151904", "Include": "true"}, {"number": "66", "ReferenceId": "32780261", "FullCitation": "Manoharan N, et al. J Neurooncol (2020) pmid: 32780261", "Include": "true"}, {"number": "67", "ReferenceId": "30097824", "FullCitation": "Kondyli M, et al. J Neurooncol (2018) pmid: 30097824", "Include": "true"}, {"number": "68", "ReferenceId": "33082744", "FullCitation": "Awada G, et al. Case Rep Oncol () pmid: 33082744", "Include": "true"}, {"number": "69", "ReferenceId": "32669708", "FullCitation": "Middleton G, et al. Nature (2020) pmid: 32669708", "Include": "true"}, {"number": "70", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "71", "ReferenceId": "25314964", "FullCitation": "Weiss B, et al. Neuro_oncology (2015) pmid: 25314964", "Include": "true"}, {"number": "72", "ReferenceId": "24931142", "FullCitation": "Janku F, et al. Oncotarget (2014) pmid: 24931142", "Include": "true"}, {"number": "73", "ReferenceId": "18164202", "FullCitation": "Johannessen CM, et al. Curr. Biol. (2008) pmid: 18164202", "Include": "true"}, {"number": "74", "ReferenceId": "15937108", "FullCitation": "Johannessen CM, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15937108", "Include": "true"}, {"number": "75", "ReferenceId": "24913553", "FullCitation": "Malone CF, et al. Cancer Discov (2014) pmid: 24913553", "Include": "true"}, {"number": "76", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "77", "ReferenceId": "20027112", "FullCitation": "Jett K, et al. Genet. Med. (2010) pmid: 20027112", "Include": "true"}, {"number": "78", "ReferenceId": "22240541", "FullCitation": "Patil S, et al. Oncologist (2012) pmid: 22240541", "Include": "true"}, {"number": "79", "ReferenceId": "23036231", "FullCitation": "Evans DG, et al. Clin Sarcoma Res (2012) pmid: 23036231", "Include": "true"}, {"number": "80", "ReferenceId": "8544190", "FullCitation": "Upadhyaya M, et al. J. Med. Genet. (1995) pmid: 8544190", "Include": "true"}, {"number": "81", "ReferenceId": "19117870", "FullCitation": "Williams VC, et al. Pediatrics (2009) pmid: 19117870", "Include": "true"}, {"number": "82", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "83", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "84", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "85", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "86", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "87", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "88", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "89", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "90", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "91", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "92", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "93", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "94", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "95", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "96", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "97", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "98", "ReferenceId": "32379280", "FullCitation": "Chen EX, et al. JAMA Oncol (2020) pmid: 32379280", "Include": "true"}, {"number": "99", "ReferenceId": "32271377", "FullCitation": "Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377", "Include": "true"}, {"number": "100", "ReferenceId": "33355200", "FullCitation": "Si H, et al. Clin Cancer Res (2021) pmid: 33355200", "Include": "true"}, {"number": "101", "ReferenceId": "34800700", "FullCitation": "Leighl NB, et al. J Thorac Oncol (2022) pmid: 34800700", "Include": "true"}, {"number": "102", "ReferenceId": "22200773", "FullCitation": "Trowbridge JJ, et al. Nat. Genet. (2011) pmid: 22200773", "Include": "true"}, {"number": "103", "ReferenceId": "21507354", "FullCitation": "Prog Mol Biol Transl Sci (2011) pmid: 21507354", "Include": "true"}, {"number": "104", "ReferenceId": "21887466", "FullCitation": "Yang J, et al. Mol Med Rep () pmid: 21887466", "Include": "true"}, {"number": "105", "ReferenceId": "16870044", "FullCitation": "Vallb\u00f6hmer D, et al. Clin Lung Cancer (2006) pmid: 16870044", "Include": "true"}, {"number": "106", "ReferenceId": "21351083", "FullCitation": "Daskalos A, et al. Cancer (2011) pmid: 21351083", "Include": "true"}, {"number": "107", "ReferenceId": "17890317", "FullCitation": "Fabbri M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17890317", "Include": "true"}, {"number": "108", "ReferenceId": "22011581", "FullCitation": "Gao Q, et al. Proc. Natl. Acad. Sci. U.S.A. (2011) pmid: 22011581", "Include": "true"}, {"number": "109", "ReferenceId": "23031157", "FullCitation": "Kim MS, et al. APMIS (2013) pmid: 23031157", "Include": "true"}, {"number": "110", "ReferenceId": "15861382", "FullCitation": "Chen ZX, et al. J. Cell. Biochem. (2005) pmid: 15861382", "Include": "true"}, {"number": "111", "ReferenceId": "25383530", "FullCitation": "Guo X, et al. Nature (2015) pmid: 25383530", "Include": "true"}, {"number": "112", "ReferenceId": "30705090", "FullCitation": "Sandoval JE, et al. J. Biol. Chem. (2019) pmid: 30705090", "Include": "true"}, {"number": "113", "ReferenceId": "29414941", "FullCitation": "Zhang ZM, et al. Nature (2018) pmid: 29414941", "Include": "true"}, {"number": "114", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "115", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "116", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "117", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "118", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "119", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "120", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "121", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "122", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "123", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "124", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_12_12 19:12:09", "OpName": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas Lin, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "5 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "13%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SOFT TISSUE", "disease_ontology": "Soft tissue spindle cell lipoma", "flowcell_analysis": "2000025857", "gender": "female", "pathology_diagnosis": "Undifferentiated spindle cell sarcoma", "pipeline_version": "v3.16.0", "purity_assessment": "12.1", "specimen": "ORD_1514792_01*US1450019.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1514792_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1450019.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4973", "cds_effect": "6139A>G", "depth": "2751", "equivocal": "false", "functional_effect": "missense", "gene": "MED12", "percent_reads": "49.73", "position": "chrX:70360579", "protein_effect": "I2047V", "status": "unknown", "strand": "+", "transcript": "NM_005120", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0063", "cds_effect": "2023_2027GTGCG>T", "depth": "2058", "equivocal": "false", "functional_effect": "frameshift", "gene": "DNMT3A", "percent_reads": "0.63", "position": "chr2:25464486", "protein_effect": "V675fs*29", "status": "likely", "strand": "_", "transcript": "NM_022552", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.4021", "cds_effect": "4081G>A", "depth": "935", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "40.21", "position": "chr12:406360", "protein_effect": "A1361T", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0458", "cds_effect": "7747_7748delAG", "depth": "4609", "equivocal": "false", "functional_effect": "frameshift", "gene": "NF1", "percent_reads": "4.58", "position": "chr17:29683985", "protein_effect": "R2583fs*12", "status": "likely", "strand": "+", "transcript": "NM_001042492", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.4931", "cds_effect": "1385G>A", "depth": "2878", "equivocal": "false", "functional_effect": "missense", "gene": "NF2", "percent_reads": "49.31", "position": "chr22:30070869", "protein_effect": "R462H", "status": "unknown", "strand": "+", "transcript": "NM_000268", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0165", "cds_effect": "2756A>C", "depth": "3221", "equivocal": "false", "functional_effect": "missense", "gene": "FAM123B", "percent_reads": "1.65", "position": "chrX:63410411", "protein_effect": "D919A", "status": "unknown", "strand": "_", "transcript": "NM_152424", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.4996", "cds_effect": "3401A>G", "depth": "2558", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "49.96", "position": "chr9:139402516", "protein_effect": "Q1134R", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0368", "cds_effect": "2821_2822insA", "depth": "2117", "equivocal": "false", "functional_effect": "frameshift", "gene": "PTCH1", "percent_reads": "3.68", "position": "chr9:98221947", "protein_effect": "I941fs*18", "status": "likely", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0591", "cds_effect": "2228G>T", "depth": "2149", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "5.91", "position": "chr2:29462673", "protein_effect": "G743V", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.491", "cds_effect": "6763_6764TC>CT", "depth": "1448", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "49.1", "position": "chr6:117609935", "protein_effect": "S2255L", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0073", "cds_effect": "625G>A", "depth": "2042", "equivocal": "false", "functional_effect": "missense", "gene": "CARD11", "percent_reads": "0.73", "position": "chr7:2983905", "protein_effect": "A209T", "status": "unknown", "strand": "_", "transcript": "NM_032415", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.5745", "cds_effect": "1312G>A", "depth": "1182", "equivocal": "false", "functional_effect": "missense", "gene": "DOT1L", "percent_reads": "57.45", "position": "chr19:2210815", "protein_effect": "A438T", "status": "unknown", "strand": "+", "transcript": "NM_032482", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.0072", "cds_effect": "853A>G", "depth": "1113", "equivocal": "false", "functional_effect": "missense", "gene": "RARA", "percent_reads": "0.72", "position": "chr17:38510599", "protein_effect": "T285A", "status": "unknown", "strand": "+", "transcript": "NM_000964", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.4822", "cds_effect": "4348G>A", "depth": "1377", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "48.22", "position": "chr19:15288391", "protein_effect": "A1450T", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"allele_fraction": "0.4815", "cds_effect": "4025G>A", "depth": "1732", "equivocal": "false", "functional_effect": "missense", "gene": "PTCH1", "percent_reads": "48.15", "position": "chr9:98209513", "protein_effect": "R1342H", "status": "unknown", "strand": "_", "transcript": "NM_000264", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": {"allele_fraction": "0.0194", "description": "FANCA(NM_000135) rearrangement intron 26", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "percent_reads": "1.94", "pos1": "chr16:89833713", "pos2": "chr16:56719952", "status": "unknown", "supporting_read_pairs": "7", "targeted_gene": "FANCA", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "5.06", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "40", "status": "unknown", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"organism": "HHV_4", "reads_per_million": "41", "status": "unknown", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}, {"organism": "HHV_8", "reads_per_million": "21", "status": "unknown", "dna_evidence": {"sample": "SQ_US1450019.01_1"}}]}}}}}